A study to evaluate post COVID-19 lung damage.
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/11/029437
- Lead Sponsor
- Medanta Institute of Education and Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients confirmed with COVID-19, admitted to Medanta-The Medicity, Gurgaon, India.
2. Patients with moderate or severe COVID 19 pneumonia, admitted to ward or ICU.
Exclusion Criteria
1. Age <18 years
2. Patients with mild COVID 19
3. Pregnant female
4. Patients with history of COVID-19 Interstitial Pneumonia treatment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie post-COVID-19 interstitial lung damage in CTRI/2020/11/029437?
How does the radiological progression of post-COVID-19 interstitial pneumonia compare to idiopathic pulmonary fibrosis?
What biomarkers are associated with long-term pulmonary function decline after SARS-CoV-2 infection in observational studies?
What are the most effective pulmonary rehabilitation strategies for post-COVID-19 interstitial damage identified in clinical research?
How do inflammatory cytokine profiles in CTRI/2020/11/029437 correlate with fibrotic changes in post-COVID-19 patients?